Improving single nucleotide polymorphisms genotyping accuracy for dihydropyrimidine dehydrogenase testing in pharmacogenetics.
Pharmacogenetics
dihydropyrimidine dehydrogenase
genotyping
Journal
Exploration of targeted anti-tumor therapy
ISSN: 2692-3114
Titre abrégé: Explor Target Antitumor Ther
Pays: United States
ID NLM: 101770662
Informations de publication
Date de publication:
2024
2024
Historique:
received:
09
11
2023
accepted:
01
01
2024
medline:
15
5
2024
pubmed:
15
5
2024
entrez:
15
5
2024
Statut:
ppublish
Résumé
Fluoropyrimidines, crucial in cancer treatment, often cause toxicity concerns even at standard doses. Toxic accumulation of fluoropyrimidine metabolites, culminating in adverse effects, can stem from impaired dihydropyrimidine dehydrogenase (DPYD) enzymatic function. Emerging evidence underscores the role of single nucleotide polymorphisms (SNPs) in
Identifiants
pubmed: 38745766
doi: 10.37349/etat.2024.00223
pmc: PMC11090686
doi:
Types de publication
Case Reports
Langues
eng
Pagination
374-383Informations de copyright
© The Author(s) 2024.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.